Asset profile
UCB7853
Biologic (subtype unspecified)
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
UCB7853 was UCB's Phase 1 Parkinson's disease candidate; its only study, NCT04651153 in healthy volunteers and PD patients, completed 2023-07-20. UCB is alive and its current pipeline page enumerates each molecule with its therapeutic area and indication; the only Parkinson's disease asset listed is glovadalen, and UCB7853 does not appear anywhere on it. Absence route, so no stop date is claimed. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 63 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| UCB7853: this drug | Phase 1 | Biologic (subtype unspecified) | alpha-synuclein | ||
| Prasinezumab | Phase 3 | Monoclonal antibody | alpha-synuclein | ||
| AFFITOPE PD01A / ACI-7104.056 | Phase 2 | Vaccine | alpha-synuclein | ||
| Exidavnemab | Phase 2 | Monoclonal antibody | alpha-synuclein | ||
| LY3962681 | Phase 1 | RNA / oligonucleotide | alpha-synuclein | ||
| UB-312 | Phase 1 | Vaccine | alpha-synuclein | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.